Displaying 1 - 12 of 23
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Metabolism, Alcohol & Toxicity
3

Siemens: Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases - ILC 2021

View
Metabolism, Alcohol & Toxicity
3

Siemens: Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases - ILC 2021

View
Metabolism, Alcohol & Toxicity
3

Siemens: Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Displaying 1 - 12 of 23